COVACTA trial raises questions about tocilizumab's benefit in COVID-19
Bryant Furlow
Topics & Concepts
TocilizumabCoronavirus disease 2019 (COVID-19)MedicinePneumoniaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBlockadeClinical trialIntensive care medicineInternal medicineVirologyOutbreakDiseaseReceptorInfectious disease (medical specialty)COVID-19 Clinical Research Studies